When Biotech Becomes Defence-Finance Relevant
The eligibility gate for resilience-fundable research
Biotechnology is increasingly entering the security perimeter of European and Allied institutions, but not every healthcare innovation belongs inside a defence-finance framework. The core problem is one of classification. A university project, diagnostic platform, medical countermeasure, biomanufacturing capability or biotech start-up becomes relevant to Defence Finance Monitor only when it supports a recognised function of resilience, preparedness, biosecurity, force health, CBRN response, critical medical supply security or crisis-management capacity. Without that institutional and operational link, the technology remains ordinary healthcare innovation, however advanced the underlying science may be.
The report is structured around a strict eligibility gate. It first defines the boundary between generic healthcare relevance and genuine defence-resilience relevance, then sets out the tests that a project must pass: recognised threat, resilience function, funding or procurement pathway, regulatory compatibility, industrial readiness and strategic-capital relevance. It then applies that framework to research domains, EU and NATO funding pathways, universities, TTOs, biotech firms, investors and regulatory actors. The final assessment explains when a biotech project should enter the DFM perimeter and when it should remain outside it.
